Arrowhead Pharmaceuticals (ARWR) free cash flow

Free cash flow · fiscal 2026
-$283.94M

Arrowhead Pharmaceuticals (ARWR) generated free cash flow of -$283.94M in fiscal 2026 (the year ended September 30, 2026). In fiscal 2025 the figure was $156.89M. Figures as of 18 Nov 2026, 12:27 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2026
-$283.94M
Highest on record
$161.03Mfiscal 2019
Lowest on record
-$604.32Mfiscal 2024
Fiscal years on record
162011–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Arrowhead Pharmaceuticals free cash flow, in more detail

Across the 16 fiscal years on record (2011–2026), the highest was $161.03M in fiscal 2019 and the lowest -$604.32M in fiscal 2024.

History · 16 fiscal years

Free cash flow by fiscal year

Arrowhead Pharmaceuticals free cash flow, year by year

Arrowhead Pharmaceuticals (ARWR) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2026-$283.94M 281.0% down
2025$156.89M—
2024-$604.32M—
2023-$330.63M—
2022-$188.91M 227.9% down
2021$147.75M—
2020-$107.75M 166.9% down
2019$161.03M—
2018-$48.64M—
2017-$31.86M—
2016-$68.29M—
2015-$67.68M—
2014-$37.13M—
2013-$19.33M—
2012-$15.82M—
2011-$7.67M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Arrowhead Pharmaceuticals and comparable companies
CompanyFree cash flowFiscal year
Axsome Therapeutics AXSM-$93.89M2025
Chemed CHE$325.48M2025
Oruka Therapeutics ORKA-$88.42M2025
Arrowhead Pharmaceuticals ARWR-$283.94M2026
MSA Safety MSA$295.43M2025
CG Oncology CGON-$132.48M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ARWR

Arrowhead Pharmaceuticals, figure by figure

Arrowhead Pharmaceuticals (ARWR) overview: price, valuation and scorecardAll health care companies by market value

Arrowhead Pharmaceuticals free cash flow: questions and answers

What is Arrowhead Pharmaceuticals's free cash flow?

Arrowhead Pharmaceuticals (ARWR) generated free cash flow of -$283.94M in fiscal 2026 (the year ended September 30, 2026). In fiscal 2025 the figure was $156.89M.

What are the highest and lowest free cash flow figures on record for Arrowhead Pharmaceuticals?

Across the 16 fiscal years on record (2011–2026), the highest was $161.03M in fiscal 2019 and the lowest -$604.32M in fiscal 2024.

How is Arrowhead Pharmaceuticals's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Arrowhead Pharmaceuticals it is on record here for 16 fiscal years, 2011 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Arrowhead Pharmaceuticals (ARWR) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/ARWR/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.